MindBio Therapeutics (XCNQ:MBIO) Change In Payables And Accrued Expense : C$0.20 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Change In Payables And Accrued Expense?

MindBio Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was C$0.01 Mil. It means MindBio Therapeutics's Accounts Payable & Accrued Expense increased by C$0.01 Mil from Dec. 2023 to Mar. 2024 .

MindBio Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2023 was C$-0.36 Mil. It means MindBio Therapeutics's Accounts Payable & Accrued Expense declined by C$0.36 Mil from Jun. 2022 to Jun. 2023 .

MindBio Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for MindBio Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Change In Payables And Accrued Expense Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Change In Payables And Accrued Expense

0.74

-0.36

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial					0.21	0.33	-0.18	0.04	0.01

MindBio Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.20 Mil.

MindBio Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.